Funding Layoffs Study Technical Review 
Xconomy
OCTOBER 7, 2016
. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. The funding could be as much as $100 million, and the first grants will be announced in 2017. —The U.S. —The U.S.
Xconomy
JULY 15, 2016
After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. All eyes are on Holmes, who is scheduled to present data from the company’s technology at a medical conference on August 1. million in funding, according to a regulatory filing. —With $1.25
Xconomy
JUNE 17, 2016
Despite technical differences and the early nature of the data that made comparison difficult, Wall Street declared Spark this week’s winner. . —More updates from the hematology meeting: Philadelphia-based Spark Therapeutics (NASDAQ: ONCE ) and Dutch firm UniQure (NASDAQ: QURE ) both updated their hemophilia B gene therapy programs.
Expert insights. Personalized for you.
77 
Let's personalize your content